A multicenter randomized controlled trial was completed in the United States to determine the safety and effectiveness of COSEAL sealant for the control of anastomotic suture hole bleeding during aortic reconstruction procedures using prosthetic vascular grafts. The proportion of suture lines sites that achieved immediate sealing and the proportion sealed within 5 minutes were determined among 37 experimental (59 sites) and 17 control subjects (27 sites).
The results of the trial indicated that greater than 80% of the total sites treated with COSEAL sealant demonstrated immediate anastomotic sealing.
A prospective, randomized, controlled multicenter trial was conducted to evaluate the safety and effectiveness of COSEAL sealant versus an absorbable gelatin sponge/thrombin hemostat to manage anastomotic suture hole bleeding in patients undergoing placement of PTFE vascular grafts. An equivalence hypothesis was used. One hundred and forty eight (148) patients were treated with COSEAL sealant or the control at nine centers. This study was designed to evaluate whether the COSEAL success rate was equivalent to the success rate for the control.
The results indicated that overall 10-minute sealing success was similar (86% vs 89%; P=.29) between COSEAL selant and the control. However, subjects treated with COSEAL sealant achieved immediate anastomotic sealing at more than twice the rate of subjects treated with the gelatin sponge/thrombin (47% vs 20%; P<.001).
A multi-center non-randomized clinical study was performed in Germany and the Netherlands with 131 patients treated in 10 centers. This trial was conducted to evaluate the safety and effectiveness of COSEAL sealant to seal anastomotic suture lines in patients undergoing placement of peripheral vascular grafts using various types of graft materials.
COSEAL is a registered trademark of Angiodevice International GmbH, used under license.